1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsTitle III-E National Family Caregiver Support Grant is sponsored by Southeastern Minnesota Area Agency on Aging (SEMAAA). Assists caregivers in caring for older individuals aged 60 and above in Southeastern Minnesota, focusing on caregiver assistance, respite services, and companion services.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Non-profit agencies and for-profit organizations (as approved by the State of Minnesota). Confirm the full requirements in the official notice before applying.
The current listing shows approximately $250,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Title III-E National Family Caregiver Support Grant is funded by Southeastern Minnesota Area Agency on Aging (SEMAAA). Verify program details on the funder's official page before applying.
This opportunity targets applicants in Minnesota. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The new ENRTF Community Grant Program offers $20,000 to $150,000 with no match and a short concept note first. How the two stages score, and who has the edge.
Read articleSeven research teams will run the first clinical trials aimed at extending human healthspan under ARPA-H PROSPR contracts worth up to $144M. The milestone-based contract model breaks every convention of federal biomedical funding.
Read articleARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read article